Without bold action now, the next pandemic is inevitable

- Novel viruses are emerging more frequently
- Viruses can emerge from anywhere
- The costs are staggering
- Response to COVID-19 continues to reveal multiple system failures

The world urgently needs a better solution.
The current system is not optimized for pandemics

- Pharma is reluctant to invest in products with no obvious market
- University research funding (e.g. NIH) is project-based aimed at point solutions
- Governments cycle between panic and neglect

To achieve pandemic preparedness, we must re-engineer antiviral therapeutic development and delivery.
The solution is READDI

READDI brings together the world’s best scientific and business minds to proactively develop and deliver novel antiviral drugs BEFORE the next virus creates another global catastrophe.
READDI is a public-private partnership

BUILT ON A PROVEN MODEL

CEPI
Vaccines
Coalition for Epidemic Preparedness

CARB-X
Antibiotics
Combating Antibiotic-Resistant Bacteria

READDI
Antivirals
Rapidly Emerging Antiviral Drug Development Initiative
What will READDI do?

**Accelerate new antiviral drug development**
- Target factors that viruses need to replicate
- Fund and facilitate projects at all stages

**Aggregate and advance existing assets**
- Identify promising antiviral compounds shelved by industry
- Develop stalled antivirals from academic labs

**Expedite treatment availability**
- Prepare Phase II & III trial design
- Identify manufacturing partners in advance

ACCELERATE. AGGREGATE. EXPEDITE.
The READDI approach

**Preparation**
- Fund cross-sector science teams
- Complete antiviral drug development through Phase I (unless existing market opportunity)
- Put promising new and existing compounds on the shelf

**Streamlined Execution**
- Licensing
- Clinical trial design completed
- Trial sites designated
- Private sector partners in place
We’re already collaborating for success

Industry Partners

University Partners

Strategic Partners

THE UNIVERSITY of NORTH CAROLINA at CHAPEL HILL

LEADING THE WAY
The research team is already at work

- 20+ active projects with partners from around the world
- Focus on multiple viral families with high pandemic potential

Project example:
- COVID-19 – Repurpose kinase inhibitors as SARS2 antiviral drugs
When the next virus emerges

On Day 1 we will have:

- Effective antiviral therapies through Phase I
- Phase II & III clinical trials designed
- Established manufacturing plan
- Helped facilitate global response and equitable distribution
Will you help us prepare for the next pandemic?

Contact

Nat Moorman: nmoorman@med.unc.edu
John Bamforth: johnph@email.unc.edu